UNSPSC 51172172: Fenpipramide hydrochloride

This classification denotes an antimuscarinic agent with the molecular formula C21H26N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KJ2V75P034, chemically known as alpha,alpha-diphenylpiperidine-1-butyramide monohydrochloride but more generally known as fenpipramide hydrochloride, which bears US NIH Compound Identifier 166974. European Medicines Agency schedules Fenpipramide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02123MIG.

Most nations, for tariff and trade purposes, schedule fenpipramide hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, FENPIPRAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenpipramide hydrochloride bears US NLM NCI C78073. SMILES: C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)C(=O)N.CL.

UNSPSC 51172172 Fenpipramide hydrochloride is a Commodity code covering a single active pharmaceutical ingredient, yet recent state and local procurement activity under this code shows minimal direct relevance. The three most recent opportunities tagged to this UNSPSC involve offender drug testing services, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical contracting—none of which explicitly solicits fenpipramide hydrochloride or name it as a required component. State and local governments appear to procure this ingredient, if at all, as a component within broader pharmaceutical product frameworks rather than as a standalone commodity, meaning opportunities are likely buried within family-level or class-level pharmaceutical solicitations rather than surfacing at the commodity tier.

Activity appears concentrated in Texas and Minnesota through state health and corrections agencies and cooperative purchasing alliances. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and estimated contract value of $600,000; the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 exploring direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026. None of these opportunities specifically names fenpipramide hydrochloride, indicating that this Commodity code shows little direct recent solicitation activity at the state and local level. Business development professionals should monitor family-level pharmaceutical codes and cooperative purchasing frameworks where ingredient-level procurement is more likely to surface.